Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1981 1
1989 1
1991 1
1992 1
1993 1
1995 1
1996 2
1997 3
1998 6
1999 4
2000 4
2001 6
2002 4
2003 11
2004 13
2005 7
2006 17
2007 13
2008 9
2009 9
2010 11
2011 12
2012 9
2013 14
2014 23
2015 33
2016 39
2017 39
2018 24
2019 24
2020 28
2021 24
2022 9
Text availability
Article attribute
Article type
Publication date

Search Results

362 results
Results by year
Filters applied: . Clear all
Page 1
The CLIP1-LTK fusion is an oncogenic driver in non-small-cell lung cancer.
Izumi H, Matsumoto S, Liu J, Tanaka K, Mori S, Hayashi K, Kumagai S, Shibata Y, Hayashida T, Watanabe K, Fukuhara T, Ikeda T, Yoh K, Kato T, Nishino K, Nakamura A, Nakachi I, Kuyama S, Furuya N, Sakakibara-Konishi J, Okamoto I, Taima K, Ebi N, Daga H, Yamasaki A, Kodani M, Udagawa H, Kirita K, Zenke Y, Nosaki K, Sugiyama E, Sakai T, Nakai T, Ishii G, Niho S, Ohtsu A, Kobayashi SS, Goto K. Izumi H, et al. Among authors: yoh k. Nature. 2021 Dec;600(7888):319-323. doi: 10.1038/s41586-021-04135-5. Epub 2021 Nov 24. Nature. 2021. PMID: 34819663 Free PMC article.
Beyond ALK-RET, ROS1 and other oncogene fusions in lung cancer.
Kohno T, Nakaoku T, Tsuta K, Tsuchihara K, Matsumoto S, Yoh K, Goto K. Kohno T, et al. Among authors: yoh k. Transl Lung Cancer Res. 2015 Apr;4(2):156-64. doi: 10.3978/j.issn.2218-6751.2014.11.11. Transl Lung Cancer Res. 2015. PMID: 25870798 Free PMC article. Review.
Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial.
Nakagawa K, Garon EB, Seto T, Nishio M, Ponce Aix S, Paz-Ares L, Chiu CH, Park K, Novello S, Nadal E, Imamura F, Yoh K, Shih JY, Au KH, Moro-Sibilot D, Enatsu S, Zimmermann A, Frimodt-Moller B, Visseren-Grul C, Reck M; RELAY Study Investigators. Nakagawa K, et al. Among authors: yoh k. Lancet Oncol. 2019 Dec;20(12):1655-1669. doi: 10.1016/S1470-2045(19)30634-5. Epub 2019 Oct 4. Lancet Oncol. 2019. PMID: 31591063 Clinical Trial.
Osimertinib in Pretreated T790M-Positive Advanced Non-Small-Cell Lung Cancer: AURA Study Phase II Extension Component.
Yang JC, Ahn MJ, Kim DW, Ramalingam SS, Sequist LV, Su WC, Kim SW, Kim JH, Planchard D, Felip E, Blackhall F, Haggstrom D, Yoh K, Novello S, Gold K, Hirashima T, Lin CC, Mann H, Cantarini M, Ghiorghiu S, Jänne PA. Yang JC, et al. Among authors: yoh k. J Clin Oncol. 2017 Apr 20;35(12):1288-1296. doi: 10.1200/JCO.2016.70.3223. Epub 2017 Feb 21. J Clin Oncol. 2017. PMID: 28221867 Free article. Clinical Trial.
Safety and efficacy of quavonlimab, a novel anti-CTLA-4 antibody (MK-1308), in combination with pembrolizumab in first-line advanced non-small-cell lung cancer.
Perets R, Bar J, Rasco DW, Ahn MJ, Yoh K, Kim DW, Nagrial A, Satouchi M, Lee DH, Spigel DR, Kotasek D, Gutierrez M, Niu J, Siddiqi S, Li X, Cyrus J, Chackerian A, Chain A, Altura RA, Cho BC. Perets R, et al. Among authors: yoh k. Ann Oncol. 2021 Mar;32(3):395-403. doi: 10.1016/j.annonc.2020.11.020. Epub 2020 Dec 2. Ann Oncol. 2021. PMID: 33276076 Free article. Clinical Trial.
Attempt at standardization of bone quantitative ultrasound in Japan.
Otani T, Fukunaga M, Yoh K, Miki T, Yamazaki K, Kishimoto H, Matsukawa M, Endoh N, Hachiya H, Kanai H, Fujiwara S, Nagai Y. Otani T, et al. Among authors: yoh k. J Med Ultrason (2001). 2018 Jan;45(1):3-13. doi: 10.1007/s10396-017-0814-5. Epub 2017 Sep 7. J Med Ultrason (2001). 2018. PMID: 28884290 Review.
[Tartrate resistant acid phosphatase].
Yoh K. Yoh K. Nihon Rinsho. 2004 Dec;62 Suppl 12:215-9. Nihon Rinsho. 2004. PMID: 15658303 Review. Japanese. No abstract available.
362 results